Relmada Therapeutics Inc（RLMD）财务数据RLMDRelmada Therapeutics Inc

Evaluating the bottom line, Relmada Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -55.66%, provide a clear picture of how effectively RLMD converts its operational activities into shareholder value.

In the context of the broader market, RLMD competes directly with industry leaders such as PBYI and OCGN. With a market capitalization of $482.15M, it holds a leading position in the sector. When comparing efficiency, RLMD's gross margin of N/A stands against PBYI's 77.88% and OCGN's 100.00%. Such benchmarking helps identify whether Relmada Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Relmada has shown significant volatility, with a 1-year change of +204.93%, but recent quarterly losses indicate ongoing financial struggles, including a net income loss of $19,051,956 in Q1 2026.